Wave Life Sciences Ltd.
WVEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Wave Life Sciences Ltd. (WVE) is listed under Biotechnology. With a market capitalization of $1.27B, it sits in small-cap territory. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Market Cap
$1.27B
Beta
-1.32
P/E (TTM)
—
P/E (Fwd)
-5.94
EPS (TTM)
$-1.05
EPS (Fwd)
$-1.11
ROE
-53.1%
ROA
-28.2%
Cash
$544.6M
Total Debt
$15.7M
Free CF
-$125.7M
52W Change
5.3%
Annual Financials
Cash vs Debt
Wave Life Sciences Ltd. holds $544.6M in cash against $15.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$125.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -53.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $41.0M (2021) to $42.7M (2025).
The relatively low beta of -1.32 suggests WVE is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, WVE has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing WVE.